HK1217698A1 - 色甘酸衍生物以及成像和治療的相關方法 - Google Patents
色甘酸衍生物以及成像和治療的相關方法Info
- Publication number
- HK1217698A1 HK1217698A1 HK16105667.3A HK16105667A HK1217698A1 HK 1217698 A1 HK1217698 A1 HK 1217698A1 HK 16105667 A HK16105667 A HK 16105667A HK 1217698 A1 HK1217698 A1 HK 1217698A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- imaging
- treatment
- related methods
- cromolyn derivatives
- cromolyn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14824509P | 2009-01-29 | 2009-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217698A1 true HK1217698A1 (zh) | 2017-01-20 |
Family
ID=42396349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105667.3A HK1217698A1 (zh) | 2009-01-29 | 2016-05-17 | 色甘酸衍生物以及成像和治療的相關方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8617517B2 (zh) |
EP (2) | EP2391618B1 (zh) |
JP (1) | JP5731406B2 (zh) |
CN (2) | CN102341391B (zh) |
AU (1) | AU2010208136B2 (zh) |
CA (1) | CA2751125C (zh) |
ES (1) | ES2733214T3 (zh) |
HK (1) | HK1217698A1 (zh) |
WO (1) | WO2010088455A2 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
CN104869993B (zh) * | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
CN103274911B (zh) * | 2013-05-09 | 2015-04-15 | 浙江金伯士药业有限公司 | 一种1,3-二羟基-2-丙酮的制备方法 |
AU2014284656B2 (en) * | 2013-05-23 | 2017-11-23 | Aztherapies, Inc. | Methods for delivering cromolyn |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
US10188757B2 (en) | 2013-10-22 | 2019-01-29 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
JP2017510624A (ja) | 2014-02-10 | 2017-04-13 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肥満細胞安定剤による全身性障害の治療 |
EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
CN114042061A (zh) * | 2015-11-19 | 2022-02-15 | 通用医院有限公司 | 包含色甘酸的组合物在制备用于治疗非遗忘性轻度认知障碍的药物中的用途 |
JP2018538273A (ja) | 2015-11-23 | 2018-12-27 | エーゼットセラピーズ, インコーポレイテッド | 虚血性脳卒中を処置するための組成物および方法 |
CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
CA3033079A1 (en) * | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
MX2020000577A (es) | 2017-07-20 | 2020-09-10 | Aztherapies Inc | Formulaciones en polvo de cromolina sodica e ibuprofeno. |
AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
MX2021006869A (es) * | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
WO2021094296A1 (en) | 2019-11-12 | 2021-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1144905A (en) * | 1965-03-25 | 1969-03-12 | Fisons Pharmaceuticals Ltd | Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof |
US3686412A (en) * | 1965-03-25 | 1972-08-22 | Colin Fitzmaurice | Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions |
GB1257162A (zh) | 1968-02-16 | 1971-12-15 | ||
US4996296A (en) | 1983-07-27 | 1991-02-26 | Yeda Research & Development Co., Ltd. | Cromolyn binding protein in highly purifed form, and methods for the isolation thereof |
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
TR199600329A2 (tr) | 1995-05-05 | 1997-03-21 | Hoffmann La Roche | Seker alkollerin yeni sülfürik asit esterleri. |
FR2815030A1 (fr) * | 2000-10-05 | 2002-04-12 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
US6511960B2 (en) | 2001-01-05 | 2003-01-28 | Alphamed Pharmaceuticals Corp | Cromolyn for eye and ear infections |
JP5196701B2 (ja) * | 2001-11-29 | 2013-05-15 | エミスフィアー テクノロジーズ インコーポレイテッド | クロモリンナトリウムの経口投与用製剤 |
US8088935B2 (en) * | 2003-12-23 | 2012-01-03 | Ironwood Pharmaceuticals, Inc. | Compounds and methods for the treatment of asthma |
AR059356A1 (es) * | 2006-02-14 | 2008-03-26 | Astrazeneca Ab | Nuevos radioligandos |
US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
-
2010
- 2010-01-29 CN CN201080011716.1A patent/CN102341391B/zh active Active
- 2010-01-29 EP EP10736439.0A patent/EP2391618B1/en active Active
- 2010-01-29 ES ES10736439T patent/ES2733214T3/es active Active
- 2010-01-29 EP EP19166810.2A patent/EP3567033A1/en not_active Withdrawn
- 2010-01-29 CA CA2751125A patent/CA2751125C/en active Active
- 2010-01-29 WO PCT/US2010/022495 patent/WO2010088455A2/en active Application Filing
- 2010-01-29 JP JP2011548321A patent/JP5731406B2/ja active Active
- 2010-01-29 AU AU2010208136A patent/AU2010208136B2/en active Active
- 2010-01-29 US US13/146,842 patent/US8617517B2/en active Active
- 2010-01-29 CN CN201510418413.6A patent/CN105061376A/zh active Pending
-
2016
- 2016-05-17 HK HK16105667.3A patent/HK1217698A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2751125C (en) | 2017-06-20 |
CN102341391B (zh) | 2015-08-19 |
EP3567033A1 (en) | 2019-11-13 |
ES2733214T3 (es) | 2019-11-28 |
CA2751125A1 (en) | 2010-08-05 |
US20120058049A1 (en) | 2012-03-08 |
AU2010208136B2 (en) | 2015-03-05 |
CN105061376A (zh) | 2015-11-18 |
EP2391618B1 (en) | 2019-04-03 |
JP2012516356A (ja) | 2012-07-19 |
AU2010208136A1 (en) | 2011-08-18 |
JP5731406B2 (ja) | 2015-06-10 |
EP2391618A2 (en) | 2011-12-07 |
EP2391618A4 (en) | 2012-07-18 |
WO2010088455A3 (en) | 2011-04-07 |
US8617517B2 (en) | 2013-12-31 |
CN102341391A (zh) | 2012-02-01 |
WO2010088455A2 (en) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217698A1 (zh) | 色甘酸衍生物以及成像和治療的相關方法 | |
HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
EP2231019A4 (en) | PHOTOACOUSTIC IMAGING DEVICES AND IMAGING METHODS | |
HK1171168A1 (zh) | 利用拉喹莫德治療克羅恩病 | |
IL236830A0 (en) | Diazahomoredene derivatives and methods of using them | |
GB0922332D0 (en) | Method of treatment and screening method | |
EP2427128A4 (en) | SURGICAL PAVEMENT COVER AND METHOD OF USE | |
IL217292A0 (en) | Polypeptides and method of treatment | |
IL214255A0 (en) | Methods and compositions for diagnosis and treatment of cancer | |
EP2464297A4 (en) | EXTERNAL ORTHOPEDIC FIXER AND USE METHOD THEREFOR | |
IL236516A0 (en) | Methods and preparations for the diagnosis and treatment of cancer | |
IL215856A0 (en) | Compositions and methods for treatment of cardiovascular disease | |
EP2464227A4 (en) | COMPOUNDS AND METHODS OF USE | |
IL206491A0 (en) | Treatment of produce | |
IL213973A0 (en) | Salt of tetrahydrotriazolopyridine derivative and crystal thereof | |
EP2491389A4 (en) | DETECTION AND TREATMENT OF NEUROTRANSMISSION DISORDERS ASSOCIATED WITH THE LRP4 RECEPTOR | |
EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
GB201120521D0 (en) | Orthotic device and method of manufacture | |
AP3078A (en) | Method and device for treatment of human excrement | |
GB0919837D0 (en) | Method of treatment and screening method | |
GB2470988B (en) | Apparatus for and methods of fishing | |
EP2440238A4 (en) | Methods of Treatment | |
GB201017857D0 (en) | Methods for diagnosis and methods of treatment | |
ZA201200077B (en) | Polypeptides and method of treatment | |
HK1174620A1 (zh) | 吲唑基取代的二氫異噁唑並吡啶及其使用方法 |